Zynrelef Indication Expanded to Include More Surgical Procedures
Zynrelef is a dual-acting local anesthetic that delivers a fixed-dose combination of bupivacaine and meloxicam.
Zynrelef is a dual-acting local anesthetic that delivers a fixed-dose combination of bupivacaine and meloxicam.
Regulora is designed to provide seven 30-minute sessions of remote behavioral therapy based on gut-directed hypnotherapy.
The investigational intranasal formulation of nalmefene demonstrated a more rapid onset and longer duration of action compared with naloxone.
The HER-MES trial included 777 adults with episodic or chronic migraine (at least 4 migraine days/month) who were treatment-naïve, not suitable for, or had previously failed up to 3 prophylactic migraine treatments.
Maxigesic is a combination of acetaminophen 1000mg and ibuprofen 300mg for IV infusion.
Seglentis is a co-crystal formulation of celecoxib, an NSAID, and tramadol hydrochloride, an opioid agonist and inhibitor of norepinephrine and serotonin reuptake.
Zimhi is intended for immediate administration as emergency therapy in settings where opioids may be present.
The analysis included 64 randomized clinical trials with a total of 46,442 patients.
In light of Pain Awareness and Arthritis Awareness Month, Lawrence Edwards, MD, discusses the importance of addressing pain in patients with gout and the role of collaboration between clinical specialties during the management of painful gout flares.
Trudhesa uses proprietary technology to deliver a lower dose (0.725mg per spray) of dihydroergotamine mesylate to the upper nasal space.